Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Its newer drugs are more than making up for the waning sales of older medications.

Roche Grows Revenue Despite Biosimilar Competition

Roche's (RHHBY) performance in 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs

Roche will release its Q4 and full-year 2019 results on Thursday, January 30, and it will likely deliver 6% earnings growth for the full year, according to our estimates. For the full year 2019, Trefis estimates that the company will report: Revenues of $63.9 billion, reflecting 5.2% y-o-y growth.

How Much Earnings Growth Can Roche Deliver?

Novartis

Sarepta Therapeutics

The number of gene therapy candidates is expected to skyrocket in the near future.

FDA Expects Explosion in Gene Therapy Treatments, Updates Review Policy

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

Roche Submits Application for Tecentriq-Avastin Combo in HCC

It's not the first bladder-cancer related setback for the drug, but it surprised industry experts nonetheless.

Roche's Tecentriq Fails to Help Patients in Muscle-Invasive Bladder Cancer Trial

Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

Roche's Urothelial Cancer Study on Tecentriq Disappoints

Strong clinical results are bolstering the odds that risdiplam will receive FDA approval this year.

Roche's Spinal Muscular Atrophy Drug Meets Primary Endpoint in Infants

Roche's (RHHBY) risdiplam meets primary endpoint in FIREFISH study in infants with type 1 spinal muscular atrophy.

Roche's Risdiplam Meets Primary Endpoint in Infants Study

Roche (RHHBY) obtains approval for Polivy in Europe for the treatment of adult patients with R/R DLBCL.

Roche's (RHHBY) Lymphoma Drug Polivy Gets Approval in Europe

Citigroup

Top Stock Research Reports for Roche, Royal Dutch Shell & Citigroup

Roche’s Avastin is the leader in the renal cancer drugs market. Renal cancer, or kidney cancer, is an important market for pharmaceutical companies, with over 73,000 new cancer cases expected in the U.S.

Roche’s $7 Billion Drug Sales At Risk?

Adobe

Alphabet

NIKE

Procter & Gamble

Mega-caps, usually the largest and most established companies in the stock market, tend to be stable, and many of them pay dividends based on their earnings.

Snap Up 5 Mega-Cap Stocks with Impressive Growth Prospects

Illumina

The two companies aim to make significant advances in cancer research and make genomics accessible to more patients.

Illumina and Roche Combine For Genomics Oncology Deal

Amarin Corporation Plc

Bristol-Myers

Blackstone Group

Clovis Oncology

Journey Medical Corp

Intuitive Surgical

Johnson & Johnson

Kaleido Biosciences Inc

Eli Lilly

Medtronic

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

Roche’s (OTCMKTS: RHHBY) stock price grew over 30% from around $30 levels by the end of December 2018 to $40 in 2019, primarily driven by expansion of the P/E multiple, along with revenue growth, a modest growth in margins, and lower share count. Roche’s stock price growth was higher than that.

What Led To A 30% Jump In Roche’s Stock In 2019?

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped last week on news that the company reached a licensing deal with Roche.

Why One Analyst Sees Sarepta’s Roche Deal Taking Off

Roche Finishes Year With Big  Deals, Gene Therapy In Focus As Competition Heats Up

Gilead Sciences

Three Roche (RHHBY) drugs with combined U.S. sales of more than $10 billion will lose patent protection in 2020.

Roche and Gilead Losing Patent Protection on Top Sellers

Johnson & Johnson and Roche (OTCMKTS: RHHBY) are both primarily engaged in the pharmaceutical business. Johnson & Johnson generated $82 billion in sales in 2018, while Roche garnered $61 billion.

How Does Johnson & Johnson’s Revenue And Other Key Metrics Compare With That of Roche?

Roche generates its revenue from sales of pharmaceuticals and diagnostics products across the globe. The company generated $24 billion in pharmaceutical sales in the United States, accounting for 53% of its total pharmaceuticals revenue in 2018.

How Much Revenue Does Roche’s Pharmaceutical Business Generate From The United States?

Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price Target

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S.

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares made a handy gain to start the week after it announced a licensing agreement with Roche.

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter's investigational gene therapy asset SRP-9001 outside of the U.S.

News for Roche Holding AG Stock (RHHBY)